Kobayashi Daijiro, Oike Takahiro, Murata Kazutoshi, Irie Daisuke, Hirota Yuka, Sato Hiro, Shibata Atsushi, Ohno Tatsuya
Department of Radiation Oncology, Gunma Prefectural Cancer Center, Gunma 373-8550, Japan.
Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan.
J Pers Med. 2020 Sep 3;10(3):110. doi: 10.3390/jpm10030110.
Micronuclei (MN) trigger antitumor immune responses via the cyclic GMP-AMP synthase-signaling effector stimulator of interferon genes (cGAS-STING) pathway. Radiotherapy induces MN in peripheral blood lymphocytes. However, data for solid tumors are lacking. Here, we analyzed MN post-radiotherapy in solid tumor samples. Tumor biopsy specimens were obtained from seven prospectively recruited patients with cervical cancer, before treatment and after receiving radiotherapy at a dose of 10 Gy (in five fractions). The samples were stained with 4',6-diamidino-2-phenylindole dihydrochloride, and 200 nuclei per sample were randomly identified and assessed for the presence of MN or apoptosis, based on nuclear morphology. The median number of MN-harboring nuclei was significantly greater in samples from patients treated with radiotherapy than in pre-treatment samples (151 (range, 16-327) versus 28 (range, 0-61); = 0.015). No significant differences in the number of apoptotic nuclei were observed between pre-treatment and 10 Gy samples (5 (range, 0-30) versus 12 (range, 2-30); = 0.30). This is the first report to demonstrate MN induction by radiotherapy in solid tumors. The results provide clinical evidence of the activation of antitumor immune responses by radiotherapy.
微核(MN)通过环磷酸鸟苷-腺苷酸合成酶-干扰素基因信号效应刺激物(cGAS-STING)途径触发抗肿瘤免疫反应。放射治疗可诱导外周血淋巴细胞产生微核。然而,关于实体瘤的数据尚缺乏。在此,我们分析了实体瘤样本放疗后的微核情况。从7例前瞻性招募的宫颈癌患者中获取肿瘤活检标本,分别在治疗前和接受10 Gy(分5次)放疗后采集。样本用4',6-二脒基-2-苯基吲哚二盐酸盐染色,基于核形态,每个样本随机识别并评估200个细胞核中微核或凋亡的存在情况。放疗患者样本中含微核的细胞核中位数显著高于治疗前样本(151个(范围16 - 327个)对28个(范围0 - 61个);P = 0.015)。治疗前样本和10 Gy放疗后样本之间凋亡细胞核数量无显著差异(5个(范围0 - 30个)对12个(范围2 - 30个);P = 0.30)。这是首份证明放疗可在实体瘤中诱导微核的报告。这些结果为放疗激活抗肿瘤免疫反应提供了临床证据。